223133-89-9Relevant academic research and scientific papers
Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification
Shinozuka, Tsuyoshi,Tsukada, Tomoharu,Fujii, Kunihiko,Tokumaru, Eri,Shimada, Kousei,Onishi, Yoshiyuki,Matsui, Yumi,Wakimoto, Satoko,Kuroha, Masanori,Ogata, Tsuneaki,Araki, Kazushi,Ohsumi, Jun,Sawamura, Ryoko,Watanabe, Nobuaki,Yamamoto, Hideki,Fujimoto, Kazunori,Tani, Yoshiro,Mori, Makoto,Tanaka, Jun
, p. 5079 - 5098 (2018/09/27)
The lead identification of a novel potent selective PPARγ agonist, DS-6930 is reported. To avoid PPARγ-related adverse effects, a partial agonist was designed to prevent the direct interaction with helix 12 of PPARγ-LBD. Because the TZD group is known to
Substituted fused heterocyclic compound
-
, (2008/06/13)
Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: wherein R1is a group of the formula (II) or (III): R4is a substituted phenyl or a pyridyl which may have a substituent. R5is hydrogen or the like. R6is hydrogen, a C1-6alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2is hydrogen or the like. R3is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.
